MicroRNAs as biomarkers for CNS disease

Pooja Rao¹, Eva Benito² and André Fischer¹,²*

¹ Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany
² German Center for Neurodegenerative Diseases Göttingen (DZNE), Göttingen, Germany

INTRODUCTION

Central nervous system disorders encompass a broad spectrum of neurodegenerative, oncological, inflammatory, and developmental conditions. Several mechanisms exist that evolved in order to isolate and protect the CNS from insult; interestingly, these effectively also act as barriers to diagnosis. Surrogate markers of disease are thus critical to facilitate disease detection, stratification of patients into subpopulations, prediction of prognosis, evaluation of response to treatment, and eventually allow better understanding of etiopathology.

To be of maximum diagnostic benefit, biomarkers would predict disease early, before the onset of clinical symptoms. Finding and testing such biomarkers would be best achieved by a longitudinal study in a large patient population at risk of developing the disease, a resource-intensive process that requires a long commitment and careful planning. However, the more common cross-sectional association studies are equally valuable in biomarker discovery. Brain imaging techniques and their modifications, as well as genotyping studies to identify susceptibility alleles—the latter frequently employed in predicting tumor prognosis—are being used successfully to understand complex neurological conditions. In parallel, as techniques evolve rapidly and new hypotheses emerge, we see novel methods being applied to biomarker discovery. Thus, with the recent rapid acceleration in the field of non-coding RNA research, the potential predictive and diagnostic uses of these molecules have also attracted significant attention. Among non-coding RNA, microRNAs have been most intensely studied and their biology has repeatedly been proven critical for diverse cellular functions. More importantly, recent evidence indicates that miRNAs can be detected in peripheral tissues and can be used to “capture” changes in the cell of origin, including neurons. This has generated substantial interest in the use of small non-coding RNAs, in particular miRNAs, as biomarkers for CNS pathology. One advantage of molecular markers such as small RNAs over imaging technology is that samples can be frozen down for retrospective analysis, which enables larger studies. This manuscript aims to provide an overview of recent advances in the field of miRNA-based biomarker discovery for CNS disease.

SOURCES OF RNA BIOMARKERS

As RNA is continually transcribed, translated, and turned over in response to physiological and pathological stimuli, the RNA profile of a cell, interpreted appropriately, could serve as a reflection of its current functional state. Current technologies enable transcriptome analysis on an unprecedented scale. In the human CNS, we often need to rely on extracranial or peripheral sources of RNA to obtain a live readout of the disease state. The choice of potential sources for representative RNA is wide and includes body fluids such as blood, plasma, or cerebrospinal fluid as well as non-neuronal tissue or cells such as lymphocytes (Figure 1). The question that arises when using non-neuronal tissue or body
FIGURE 1 | A model for miRNA-based biomarker development: Disease-causing factors impact the brain both directly and indirectly (via immune and other cells), eliciting changes in gene and microRNA expression patterns. Many of these stimuli concurrently exert their influence on non-neuronal cells, where they also elicit a response. In CNS diseases, in the absence of direct access to diseased tissue, microRNA expression patterns from peripheral cells such as blood cells could be used as a proxy for genome-environment interaction in the CNS. Moreover, microRNAs circulate stably in cerebrospinal fluid and plasma in extracellular vesicles and in lipoprotein complexes, and can be isolated from these body fluids and profiled. Information derived from peripheral sources could thus be used to construct a picture of neuronal function both in the healthy and the diseased state.

RNA FROM BLOOD CELLS
The use of genetic material from blood cells to screen for biomarkers of neurological conditions has been used as early as 1975 (Issidorides et al., 1975). Peripheral blood mononuclear cells (PBMCs), one of the major cellular components of blood, are particularly interesting in the context of biomarkers due to their ability not only to respond to internal and external stimuli, but also to “store” the information at the epigenetic level (Tang et al., 2001; Gavin and Sharma, 2009, 2010). Studies in monozygotic twins have demonstrated that over time PBMCs accumulate differences at the DNA methylation and histone acetylation level (Fraga et al., 2005). Furthermore, PBMCs have been successfully used to characterize the disease biosignature in neuropsychiatric conditions such as schizophrenia and bipolar disorder (Tang et al., 2001; Segman et al., 2005; Tsuang et al., 2005; Bowden et al., 2006; Iga et al., 2006; Anderson et al., 2008). Several lines of evidence suggest that both brain and blood cells can respond to environmental stimuli and reflect this response at the epigenetic level in their genome and that this response is indeed to some extent concordant between both tissue types (Desjardins et al., 2008; van Heerden et al., 2009; Li et al., 2011; Ursini et al., 2011; Yuferov et al., 2011; Davies et al., 2012; Provencal et al., 2012). Firstly, gene expression profiles in PBMCs have revealed common patterns of transcriptional activity in blood and neurons (Sullivan et al., 2006). Thus, for example, DNA methyltransferases DNMT1 and DNMT3a have been found to be upregulated in both post-mortem brain tissue and PBMCs from schizophrenia patients (Zhubi et al., 2009) and whole chromosome mRNA expression profiles were found to be partially consistent between blood and brain in Huntington’s disease patients (Anderson et al., 2008).
mice, a model of early life stress (i.e., maternal separation) was shown to induce a concordant transcriptional response in PBMCs and several brain regions (Desjardins et al., 2008).

Further, transcriptomic information obtained in peripheral blood has been successfully applied to predict healthy/disease status or to differentiate between disease stages (Tang et al., 2001; Tsuang et al., 2005; Du et al., 2006; Desjardins et al., 2008). This is possible due to the fact that PBMCs and neurons are actually exposed to very similar biochemical environments and can thus mount a concordant cellular response to incoming stimuli. Interestingly, in most of these cases, genes found to be differentially expressed in blood were also directly associated with neuropsychiatric disease and to be altered in postmortem brain (Tang et al., 2001; Tsuang et al., 2005; Du et al., 2006; Desjardins et al., 2008).

Secondly, the levels of certain epigenetic markers, such as DNA methylation patterns or miRNA expression, have been shown to directly correlate between PBMCs and neuronal tissue. A recent study by Davies and colleagues demonstrated a globally correlated inter-individual pattern of DNA methylation between cortical brain areas and PBMCs in healthy human postmortem tissue (Davies et al., 2012). In Rhesus monkeys, a model of early life stress based on surrogate mother rearing induced significant changes in DNA methylation in the prefrontal cortex, as well as in PBMCs (Provençal et al., 2012). Although the response in brain was more drastic, a positive and significant correlation in epigenetic changes was found between both tissue types (Provençal et al., 2012). At the individual gene level, the prodynorphin promoter has also been recently shown to display a consistent methylation pattern between blood cells and caudate/cingulate cortex in human post-mortem tissue (Ursini et al., 2011) and changes in methylation observed in human blood samples within the COMT gene (Catechol-O-methyltransferase, a critical enzyme for dopamine processing in the brain) were replicated and significantly correlated between blood and prefrontal cortex in the orthologous genomic location in rats (Li et al., 2011). Additionally, there is evidence to suggest that the level of other epigenetic markers, such as miRNA levels, also show parallel patterns of expression in blood and brain. Thus, levels of miR34a were recently shown to increase during aging in blood PBMCs, as well as in plasma and brain, and to correlate with a concomitant decrease in SIRT1 expression, one of the main targets of this miRNA (van Heerden et al., 2009).

Taken together, there is a solid base to suggest that PBMCs and perhaps other blood cells have the potential to provide a transcriptional and epigenetic biosignature that can be useful for both biomarker development and drug discovery and that these can be used as a proxy to study epigenetic mechanisms of neuropathology and its progression.

EXTRACELLULAR RNA

After the discovery that cells export RNA packaged in 40–90 nm sized vesicles called exosomes, and that this RNA could be taken up and translated by recipient cells (Valadi et al., 2007), extracellular vesicles rapidly attracted attention as a potential medium for intercellular communication. Similar findings in exosomes from primary glioblastoma cells, indicating that malignant vesicles may play a role in modulating tumor microenvironment (Skog et al., 2008), brought researchers to the idea of using the information carried by these vesicles to study organs/tumors remotely. Cell-derived RNA can also be found in a host of other membrane enclosed vesicular bodies variously called nanovesicles (Kogure et al., 2011), shedding vesicles, microvesicles (Ratajczak et al., 2006), or microparticles (Patz et al., 2013).

Exosomal and other extracellular vesicles are known to play a role in neuronal function, but the nature and degree of their involvement is still being studied. Exosomal release is modulated by glutamatergic synaptic activity, indicating that this may be a part of normal synapse physiology, and that the contents of these vesicles could be relevant for interneuronal communication (Lachenal et al., 2011). Exosomes also play a role in signaling between the pre- and post-synapse. Exosomal transfer of synaptotagmin 4 from the pre- to the post-synaptic compartment enables the presynapse to influence postsynaptic retrograde signaling (Korkut et al., 2013). These and several other lines of evidence led to the hypothesis that intercellular communication via exosomal content is a key underexplored physiological mechanism in the nervous system (Smallheiser, 2007). Thus, the RNA content of brain-cell-derived vesicles is a promising source of biomarkers for CNS disease. Extracellular RNA can also be found outside vesicles (Wang et al., 2010), in complex with lipoproteins such as HDL (Vickers et al., 2011) or with Argonaute2 (Arroyo et al., 2011; Turchinovich et al., 2011). This population comprises primarily miRNA, which appears to circulate stably in this form (Mitchell et al., 2008).

Recently, evidence that extracellular RNA can be extracted from various body fluids including saliva (Palanisamy et al., 2010), plasma (Hunter et al., 2008), urine (Alvarez et al., 2012), and CSF (Patz et al., 2013) has accumulated (Figure 1). Next generation sequencing (NGS)-generated profiles of the RNA contents of extracellular vesicles are beginning to be published (Burgos et al., 2013; Ogawa et al., 2013). However, the cellular source of this RNA is not always clear. RNA isolated from body fluids is likely to originate from a heterogenous mixture of cell types. The majority of RNA that circulates in the plasma is presumably of hematologic or endothelial cell origin, and the degree to which other tissues contribute is difficult to estimate. Studying the degree of variation of circulating miRNA molecules from the canonical sequence (the so-called isomiR profile) could allow an estimation of relative contributions of its tissue of origin (Williams et al., 2013). Although CSF is a relatively closed system, the cellular subpopulation of origin of CSF vesicles is also heterogenous, comprising vesicles derived from oligodendrocytes (Scolding et al., 1989), microglia, and macrophages (Verderio et al., 2012) as well as neurons (Saman et al., 2012).

Rapid progress is currently being made in the relatively new field of extracellular RNA isolation and profiling. Body fluids such as blood or CSF are thus likely to be a rich future source of small RNA biomarkers for CNS disease (Figure 1).

CURRENT microRNA DETECTION AND ANALYSIS TECHNOLOGIES

CNS biomarker studies have employed RNA from several different sources, and the decision about choice of source RNA involves
several factors. Using whole blood, serum, or plasma is clearly a minimally invasive approach and for those trying to develop or test a biomarker, these samples are probably easiest to access from registries or biological material repositories. Moreover, for ultimate clinical use, an accurate blood-based biomarker would be highly valuable. On the other hand, the presence of the blood-CSF barrier makes it likely that molecular entities isolated directly from CSF are more accurate reflections of brain physiological and pathological processes. Thus, RNA from CSF could be a more sensitive marker of changes that are diluted when trying to detect them in peripheral tissue. Using non-coding RNA as a molecular marker for disease involves several steps: The RNA must be isolated from the source and purified, enriched, or amplified before it is quantified, analyzed, and connected back to biological function. At each step of the process a formidable array of alternatives exists, and technologies in this field continue to evolve rapidly.

EXTRACELLULAR RNA ISOLATION METHODS

RNA can be extracted from extracellular vesicles with relative ease, using one of several methods. The most commonly used isolation methods employ commercial kits based on a combination of a lysis step and column precipitation. Guanidinium thiocyanate-phenol-chloroform extraction is also effective, either by itself or in combination with a column. Most methods result in high quality and pure RNA, equally compatible with most downstream applications. However, each method results in a different RNA yield, in terms of quantity as well as RNA size profile (Eldh et al., 2012). One possible reason for that is that all the current vesicular isolation methods yield a heterogenous mixture of vesicles that vary in intracellular source (cell membrane vs. endosomal), RNA content, and lipid membrane composition. The difference in membrane composition likely translates to a difference in susceptibility to lysis, as different buffers are likely to target vesicle subpopulations with varying degrees of efficacy. Moreover, some of the commercially available methods are specifically designed to enrich small RNA species, while others are non-selective. The outcome is that the RNA population used for biomarker studies depends heavily on the RNA extraction method employed.

These differences in isolated RNA species are even wider when RNA is isolated directly from serum, plasma, CSF, or other biological fluids. The miRNA content is likely to include protein and lipid-complex associated free RNA in addition to vesicular RNA. A comparison of RNA extraction methods used directly on plasma and CSF showed large differences in yield (Burgos et al., 2013). The degree of variation in RNA size profile and content is not clear.

RNA can also be isolated from whole blood using commercially available tubes designed for the purpose. A comparison of 2 commercial kits using proprietary lysis reagents for direct RNA isolation from peripheral blood found that the overlap between the results obtained (in terms of gene expression changes) could be as low as 46% (Menke et al., 2012); this effect is particularly pronounced when the fold change in gene expression is small (Asare et al., 2008).
complex analysis, the major disadvantages relate mainly to scalability and input material requirements. One of the steps in sample preparation is PCR amplification. It is a well-known source of biases and, if overdone, can cause excessive duplication levels, which leads to information loss during the analysis. Although the amount of input material is generally not problematic in most model system approaches, when dealing with human tissue, and, in particular, in the field of biomarker development, where sample access is limited (i.e., in the case of blood or cerebrospinal fluid), the ability to scale down starting material requirements is critical. The field of small RNASeq is still under heavy development and there is reason to believe that downscaling can indeed be achieved with high fidelity, at least pertaining to miRNA detection (authors’ unpublished data). As sequencing technologies continue to develop, we will be able to detect small RNAs from very low amounts of starting biological material.

**DATA ANALYSIS AND PATTERN DISCOVERY**

RNA-Seq data analysis entails serial steps including quality control, alignment to reference genome, read quantification (read counting), and statistical comparison of conditions of interests (Pepke et al., 2009). A comprehensive review of the method is out of the scope of this article, but it is worth mentioning that in the case of small RNAs, there are some additional considerations to be made. Because of the short length of target molecules, sequencers will read into the adapter primers used during the library preparation. These sequences have to be trimmed before alignment, since they would otherwise interfere with this step. The alignment step itself is also distinctive from the approach generally taken for RNA-Seq. Although alignment to the genome is possible, most current strategies take a hierarchical approach in which reads are serially aligned to different databases of small RNA species. After alignment, read counting and differential expression analysis can be carried out using standard procedures as those used in RNASeq (Pepke et al., 2009). Although the analytical procedure for small RNASeq is still under development, a number of publicly available tools exist that deal with the most standard approaches [the pros and cons of some of which are reviewed in Zhou et al. (2011)].

As small RNA studies evolve from investigation of single candidates to global transcriptional profiling, novel methods of analysis need to be adopted to interpret the large amounts of data generated. When targeted approaches are used, investigators typically use p-values or p-values corrected for multiple testing. With larger datasets, where differential expression analysis is the norm, filtering, and normalization is often of critical importance. These data also lend themselves very well to machine learning approaches, which have already been used in miRNA biomarker studies for multiple sclerosis and glioblastoma (Roth et al., 2011; Noerholm et al., 2012).

In biomarker research, the most commonly used unsupervised learning approaches are clustering and principle component analysis (PCA), typically used to detect a feature pattern without prior knowledge about sample grouping. In situations where the RNA profiles of the groups under comparison exhibit a high level of dissimilarity, they cluster into distinct groups by an unsupervised clustering algorithm. Alternatively, a “modified unsupervised clustering” where clustering is performed after feature selection may also be used (Noerholm et al., 2012). In most studies, the differences in RNA expression profiles are often subtle, requiring selection of candidates followed by application of supervised machine learning algorithms. Optimally applied, supervised machine learning algorithms such as support vector machines (the most popular so far in RNA biomarker studies), random forests, or artificial neural networks are trained to make classifications based on selected features and then tested on an independent data set to estimate prediction accuracy. However, flawed application of these specialized analysis techniques can lead to reporting of falsely high accuracy rates, hindering reproducibility.

For biomarkers to be used in the clinical setting, they should be applicable (with a certain margin of error) to a single individual. Therefore, predictions of sensitivity, specificity, and accuracy are often more useful than estimates of significant differences between patient and control groups.

**LANDMARK CNS BIOMARKER WORK**

Blood cells, plasma, and CSF have all been used as starting material to develop miRNA biomarkers for CNS malignancies as well as neurodegenerative and other neurological diseases. One of the first studies to compare miRNA profiles from blood mononuclear cells between patient and control populations showed mir-34a and mir 181b to be upregulated in mononuclear cells from the blood of patients with Alzheimer’s disease. In addition, gender and APOE4 status were also found to influence the PBMC miRNA profiles within the group of AD patients (Schipper et al., 2007). This approach has since been used to identify potential biomarkers for other CNS diseases such as multiple sclerosis, schizophrenia (Lai et al., 2011; Gardiner et al., 2012), Parkinson’s disease (Martins et al., 2011; Soreq et al., 2013), and amyotrophic lateral sclerosis (De Felice et al., 2012). For multiple sclerosis in particular, a large number of studies exist that profile miRNA in peripheral blood immune cells (Keller et al., 2009; Cox et al., 2010; De Santis et al., 2010; Lindberg et al., 2010; Martinelli-Boneschi et al., 2012).

Plasma and serum have also been investigated as a source of miRNA biomarkers for multiple sclerosis (Siegel et al., 2012). Cerebrospinal fluid miRNA has been studied in Alzheimer’s disease (Cogswell et al., 2008), multiple sclerosis (Haghikia et al., 2012), and to a larger extent in glioblastoma (Baraniskin et al., 2010; Teplyuk et al., 2012). A single study of miRNA in pooled CSF microparticles from patients with neurotrauma showed that the contents of CSF could also be useful in diagnosing brain injury (Patz et al., 2013) (Table 1). Among the CNS malignancies, a variety of starting biological materials has been used; the majority of studies investigate samples from patients with glioblastoma, probably because drawing CSF pre and post-operatively is routine procedure in glioblastoma diagnosis. (Roth et al., 2011; Baraniskin et al., 2012; Ilhan-Mutlu et al., 2012; Teplyuk et al., 2012; Wang et al., 2012), and a single study of patients with astrocytoma (Yang et al., 2013) (Table 1).

Over the last year there has been a sharp increase in published studies about circulating microRNA as biomarkers for various...
| Disease                  | Patient population                                                                 | Biological Material | RNA isolation and detection                      | Statistical Analysis                                                                 | Prediction and accuracy estimation | Results                                                                 | Reference                          |
|-------------------------|------------------------------------------------------------------------------------|---------------------|--------------------------------------------------|-------------------------------------------------------------------------------------|-----------------------------------|------------------------------------------------------------------------|------------------------------------|
| Glioma                  | 10 patients with glioma versus 10 controls with other neurological disorders, primary diffuse large B-cell lymphoma of the CNS (PCNSL), brain metastases | CSF                 | miRVana RNA kit (Ambion) gPCR                    | Mann-Whitney U tests and Kruskal-Wallis tests with Dunn’s multiple comparison       | RDC analysis and decision trees | MR1-155 and MR1-21 were differentially expressed in CSF samples from patients with gliomas | Baranisik et al., 2012             |
| Glioblastoma            | 10 Patients with glioblastoma versus 50 patients with other brain malignancies versus 10 healthy controls | Plasma              | miRcode miRNA isolation kit gPCR                  | Mann-Whitney test                                                                   | RDC curves                         | MR1-21, MR1-128 and MR1-340-3p were significantly altered in gliomas and in glioblastoma multiforme | Wang et al., 2012                  |
| Astrocytoma             | 122 Patients with astrocytoma grades II-IV and 123 healthy controls                | Serum               | Trizol                                           | Solexa sequencing, followed by qPCR validation in an independent cohort              | Student’s t-test and ANOVA         | ROC curves for each miRNA and for the group of microRNAs               | Yang et al., 2013                  |
| Glioblastoma            | 20 patients Glioblastoma versus 20 healthy controls                                 | Cellular fraction of whole blood | miRNeasy Mini Kit (Qiagen) Microarray             | Unpaired two-tailed parametric t test. P-values obtained for each individual miRNA were adjusted for multiple testing by Benjamini-Hochberg | Support vector machines algorithm | 52 miRNAs differentially regulated                                    | Roth et al., 2011                  |
| Glioblastoma            | 10 patients with glioblastoma and 10 healthy volunteers                            | Plasma              | Exion microRNA isolation protocol Taqman qPCR     | Mann-Whitney U test and Paired t test                                               | None                              | MicroRNA-21 is raised in the plasma of patients with glioblastoma and decreases significantly after surgical tumor removal | Ihan-Muhu et al., 2012             |
| Glioblastoma and brain metastases | 19 Patients with glioblastoma versus 15 controls with non-neoplastic brain conditions | CSF                 | miRVana RNA kit (Ambion) Taqman qPCR             | Wilcoxon signed rank test                                                          | Support vector machines algorithm | MR1-10b Is Present and MR1-21 Is Elevated in CSF of Glioblastoma and Brain Metastasis | Teplyuk et al., 2012               |
| Parkinson’s disease     | 19 Parkinson’s disease patients and healthy controls                               | pBMCs               | miRNeasy Mini Kit (Qiagen) Microarrays, validated by qPCR | Differential expression analysis, Combined with alphasyn chromatin ChIP-Seq for pathway analysis | None                              | 18 miRNAs differentially expressed,                                   | Martins et al., 2011              |
| Parkinson’s disease     | 7 patients Parkinson’s disease before and after deep brain stimulation versus 6 healthy controls | Leukocytes          | Leukolock RNA isolation kit (Ambion) SOLID RNA sequencing | Differential expression analysis, Followed by combinatorial analysis with splice-junction and exon arrays to generate a miRNA-spliced target disease network | None                              | 16 microRNAs differentially expressed in patients versus controls, 11 microRNAs changed after DBS, 5 of these overlapped/reversal of miRNA pattern to healthy after DBS | Sorens et al., 2013                |
| Alzheimer’s disease     | 6 AD patients (breaks stage 5) and 9 non-demented controls (Breaks stage 1)         | CSF                 | Proprietary qRT-PCR based methods(Aurange n) Taqman qPCR array | Between Groups Analysis, t test                                                    | None                              | Sixty miRNAs differentially expressed between early AD and advanced AD, including all members of the MR1-30 family | Cogswell et al., 2008              |
| Alzheimer’s disease     | 20 AD patients versus 22 controls                                                  | CSF                 | miRCURY kit for biofluids Taqman qPCR            | Differential expression, two-tailed t test                                          | ROC curves                         | has MR1-146b decreased in the CSF of AD patients                       | Müller et al., 2014                |
| Pathology                          | Sample Source | miRNA Detection | Analysis | Reference                  |
|-----------------------------------|---------------|-----------------|----------|----------------------------|
| Alzheimer's disease               | CSF           | TRIzol reagent  | Analysis of Variance (ANOVA) | None | Hsa-miR-9, -125b, -146a, -155, -34a and -28 higher in AD than in controls | Alexandrov et al., 2012 |
|                                   | plasma        | MicroRNA array  |          |                            |                                |                        |
|                                   | Whole blood   |                 |          |                            |                                |                        |
|                                   | Carabba CA    | RNA sequencing  | Wilcoxon-Mann-Whitney test followed by correction for multiple testing by Benjamini-Hochberg adjustment | Radial basis function support vector machines, ROC curves | 12-miRNA signature (hsa-miR-7, 5p, hsa-miR-76, 3p, hsa-miR-128-5p, 107, 103a-3p, 26b, 50, 26a, 50, 532-5p, -151-3p, -161, -112, -5010, 50) | Ledingue et al., 2013 |
|                                   | Isolation kit | Nanostar nCounter miRNA expression assay, validated by qPCR |          |                            |                                |                        |
|                                   | 2 independent cohorts (11 AD, 9 MCI and 20 healthy controls) | |          | Linear discriminant analysis, Individual and group microRNA ROC curves in independent cohort | 7-miRNA signature (hsa-miR-7, 5p, hsa-miR-76, 3p, hsa-miR-128-5p, -151-3p, -112, -5010, 50) | Kumar et al., 2013 |
| Alzheimer's disease and mild cognitive impairment | Serum | miRNeasy Mini Kit (Qiagen) and mirVana MeltEx Cleanup Kit (Qiagen) | miScript SYBR Green PCR | Differential expression, 2 tailed t tests and Mann-Whitney test | None | Hsa-miR-137, -181c, -9, -29a and -29b were downregulated in both AD and mild cognitive impairment when compared to controls | Gieysynage et al., 2012 |
|                                   | Trizol with miRNeasy Mini columns | Microarray with qPCR validation | Significance Analysis of Microarrays | None | Hsa-miR-34a and -181b higher in AD | Schipper et al., 2007 |
| Alzheimer's disease               | PBMCs         | mQPCR           | Mann-Whitney U-tests of MicroRNA pair ratios compared in the 3 groups | ROC curves for miRNA pairs | Two sets of mRNA pairs (hsa-miR-126-5p, 132-3p, 491-5p and -128-3p, 570, -223-3p, 370 and -302-3p) differentiate AD from controls but not from each other | Shellerman et al., 2012 |
|                                   |              |                 |          |                            |                                |                        |
| Multiple Sclerosis                | CSF           | miRNeasy Mini Kit (Qiagen) and microarray based method (Agilent) | Microarray | t tests with Benjamini-Hochberg correction for multiple testing | SVM | 165 miRNAs differentially regulated, hsa-miR-145 emerged as the best single differentiating microRNA | Keiler et al., 2009 |
|                                   |               | qPCR array, miRAT+ confirmed by qPCR | Mann-Whitney U tests | Mann-Whitney U-tests of MicroRNA pair ratios | ROC curves | Multiple differentially expressed miRNAs were identified in MS -181c and -633 could differentiate relapsing-remitting from secondary progressive MS | Haghikia et al., 2012 |
| Multiple Sclerosis                | plasma        | Microarray      | Mann-Whitney U tests | Mann-Whitney U-tests of MicroRNA pair ratios | ROC curves | Mann-Whitney U-tests of MicroRNA pair ratios | Haghikia et al., 2012 |
| Multiple Sclerosis                |               |                |          |                            |                                |                        |
| Multiple Sclerosis                | PBMCs         | miRNeasy Mini Kit (Qiagen) | Microarray | Discovery sample and verified in replication sample, Wilcoxon rank sum test and one way ANOVA test, including Holm-Sidak for multiple comparisons | None | 104 miRNAs deregulated, only let-7g and miR-150 confirmed by qPCR Combined with miRNA expression analysis | Martinelli-Bonetti et al., 2012 |
| Multiple Sclerosis                | CD41 lymphocytes | miRNeasy Mini Kit (Qiagen) | TaqMan Array, validated by ligation qPCR in a separate cohort | Differential expression analysis | None | Ten, four and six differentially expressed miRNA in CD41+, CD8+ and 8-lymphocytes, respectively, of MS compared with HIV, hSVM-17-5p upregulated in MS patients confirmed in validation set | Lindberg et al., 2010 |

(Continued)
| Neurological Condition | Study Details | Microarray Technique | Differential Expression Analysis Method | Significant Changes | References |
|------------------------|---------------|----------------------|-----------------------------------------|---------------------|------------|
| Multiple Sclerosis     | 12 Relapsing-remitting MS patients versus 14 healthy controls, validated in a separate cohort | TRIzol® Plus RNA purification Kit, Agilent Human miRNA microarray | Differential expression analysis followed by the application of the Benjamini and Hochberg correction | 23 human miRNAs differentially expressed between CD4+CD25high FoxP3 Treg cells from MS patients vs. healthy donors | De Santis et al., 2010 |
| Multiple Sclerosis     | 59 MS patients and 37 controls Whole blood | Paired-pair collection followed by tissue isolation | Illumina sentrix array matrix, microarray | Significance Analysis of Microarray | None |
| Multiple Sclerosis     | Patients with relapsing-remitting multiple sclerosis and controls | Nucleoscript miRNA kit (Macherey-Nagel) | Microarray analysis by test for differential expression, qPCR analyzed by Mann-Whitney-U ROC curves test | Has-miR-145 was 3-fold upregulated in MS patients | Sandegaard et al., 2013 |
| Multiple Sclerosis     | 15 MS patients and 12 Controls PBMCs and serum | Maxilena Paris kit (Amolen) | Taqman qPCR, Student’s t test | Levels of has-miR-223 and -223a were significantly altered in PBMCs and serum of MS patients | Rizoli et al., 2013 |
| Amyotrophic lateral sclerosis | 8 ALS patients and 10 healthy controls with an independent validation cohort (14-16) leukocytes | Trizol reagent, microarray | Differential expression analysis of microarray | 8 miRNAs that were significantly up- or downregulated in ALS patients | De Polito et al., 2012 |
| Schizophrenia          | Learning set of 30 cases and 30 controls, validated in an independent testing set of 60 cases and 30 controls PBMCs | Trizol reagent, microarray with qPCR validation | Wilcoxon rank-sum test, followed by stepwise logistic regression analysis | seven-miRNA signature (hsa-miR-9a, -449a, -554, -432, -348c, -572 and -652) was derived | Lai et al., 2011 |
| Schizophrenia          | 112 schizophrenia patients and 76 controls with no psychiatric illnesses PBMCs | Trizol reagent, microarray platform (Illumina), validated by Significance analysis of microarray qPCR | Logistic regression analysis, SVM, ROC curve | Set of deregulated microRNAs originating from a single imprinted locus at the maternally expressed ILK1-01D3 region on chromosome 14q32 | Gardner et al., 2012 |
| Manic episodes, bipolar disorder | 21 patients and 21 controls Plasma | Acid phenol/chloroform extraction, Taqman qPCR | ANOVA test with Tukey post-test | Has-miR-134 is decreased in patients with a manic episode and levels go back to normal in patients treated for 4 weeks. | Rong et al., 2011 |
| Depression              | 40 Patients with depression and 40 healthy controls | Serum extraction, SYBR green qPCR | Wilcoxon rank sum test | Hsa-miR-132 and -182 are raised in patients with depression | Li et al., 2013 |
neurological diseases. Many of these used unbiased, genome-wide profiling approaches to compare patients with controls and derive. For Alzheimer’s disease alone there are now a total of 5 published studies from various blood fractions and 3 from CSF. While these individual studies report high accuracy rates, and some of them include large numbers of patients, it is curious that their results do not match or even overlap with each other. The blood studies all used different fractions of blood and comparisons are perhaps unrealistic, but the CSF studies also showed differing results. For example, hsa-miR-146a is reported in one of the 3 studies to be upregulated in AD (Alexandrov et al., 2012), in a second study to be downregulated (Müller et al., 2014), while the third shows no effect on it at all, reporting a downregulation of hsa-miR-146b instead (Cogswell et al., 2008) (Table 1). Perhaps in the future, a larger number of studies and their metanalysis would shed more light on which non-coding RNAs are truly useful biomarkers of disease.

FROM BIOMARKERS TO FUNCTION

Although several classes of non-coding RNA have been discovered (Taft et al., 2010), miRNAs are the most extensively characterized. Computational tools that predict miRNA targets are quite frequently used to ascribe function to putative miRNA biomarkers. Since miRNAs and the genes they target are expressed in a tissue- and pathology-specific manner, predicted targets usually require experimental confirmation. Tools that combine prediction algorithms with large scale wet lab experimental methods such as polysome profiling, immunoprecipitation of members of the RISC complex or degradome sequencing are likely to provide more specific results (Thomson et al., 2011). Since the publication of a miRNA mRNA map based on argonaute HITS-CLIP data from the brain (Chi et al., 2009), more specific predictions are also available.

As our understanding of non-coding RNA biology develops, we see that miRNAs are evolutionarily conserved across species but have overlapping targets and are often functionally redundant. While landmark advances have been made toward understanding the role of single miRNAs in the CNS (Kim et al., 2007; Rajasethupathy et al., 2009; Ed Bauer et al., 2010; Zovoilis et al., 2011), we see a gradual shift from studying the single-miRNA-target interaction toward viewing these critical regulators as part of a network, tuning or buffering key gene regulation node (Zhang and Su, 2009).

Clearly, miRNAs exert their influence on biological pathways in concert with transcription factors and other modulators of gene expression. A few of the more recent biomarker studies attempt to view the larger picture by concurrently profiling miRNA expression, gene expression, and protein-DNA interaction. In particular, researchers studying biomarkers for Parkinson’s disease have pioneered these analyses by combining miRNA expression with tissue-specific gene isoform expression (Soreq et al., 2013) or data from ChIP-sequencing data with miRNA target prediction (Martins et al., 2011) to build a picture of the regulatory network in health vs. disease.

Biomarkers are ultimately validated when they can be connected with molecular mechanisms across different levels of biological complexity. A systems biology approach could achieve this by integrating data, where it is available, across different levels such as genes, molecules, phenotypes, cell, and tissues. Various computational tools are available to integrate these data types and more are being developed (Villoslada and Baranzini, 2012). Simple, readily available and widely used methods to link a set of differentially expressed genes with biological processes or pathways include gene ontology term search and gene set enrichment analysis. The availability of large and complex data sets and computing power has spurred rapid advances in network biology.

Moreover, RNA data can be analyzed in combination with patient information, disease history, genomic data like APOE4 allele, disease-specific clinical tests like MEP (motor-evoked potential for MS or mini-mental state examination for dementia), and data from proteomics and other high throughput approaches. Proteomics-based biomarkers for neurodegenerative and other neurological diseases have been studied and new avenues for biomarker discovery such as metabolomics continue to emerge; an LC/MS based approach (Trushina et al., 2013) to study the metabolic profiles of CSF and plasma from AD patients found around 150 metabolites each in CSF and plasma that were significantly different in patients with Alzheimer’s disease or patients with mild cognitive impairment (MCI) than healthy individuals, allowing them to identify putative pathways that may be altered (Trushina et al., 2013). These kinds of data could lend themselves to a combinatorial analysis provided that patient information and other variables are fully documented and available.

CURRENT LIMITATIONS AND FUTURE MILESTONES OF miRNA-BASED BIOMARKER DISCOVERY

The use of non-coding RNA and miRNA in particular has gained significant attention since the discovery that these RNA species can be detected extra- and intracellularly in peripheral tissue. The growing use of powerful detection methods such as massive sequencing has given a significant boost to the search for minimally invasive disease indicator. In addition, the discovery of the existence of free or exosomal circulating RNA in blood and CSF has also fostered research in this direction. Although this is still a relatively young field, it is rapidly evolving and promises great advances in the field of biomarker discovery, especially for nervous system pathology. The CNS is the least accessible of all tissues and would therefore greatly benefit from advances in this field. Current limitations to this approach include those inherently associated with biomarker discovery (i.e., working with material from different sources, extraction methods, patient history, etc.), as well as those specifically associated with sequencing-based detection methods and extraction strategies.

As is often the case when working with human tissue, samples from different sources show wide variability in profile as a result of handling, sample preparation and preservation. These are especially pronounced when a highly sensitive technique like sequencing is used. In addition, because the source of tissue are primarily human patients that may be on medication, proper consideration of these (potentially confounding) cofactors is essential, as medication pursues restoration of the biological balance and this may include alterations in the molecule of interest. When RNA profiles are altered after drug treatment, it can be a challenge to dissect the direct effects of treatment on RNA expression from
those connected with disease remission (Rong et al., 2011). An analysis of highly cited (more than 400 citations) biomarker publications (including protein, genetic, and other blood biomarkers) showed that individual studies usually report high association between the marker and disease outcome; however, when the same biomarker is subsequently compared with larger studies or meta-analyses, the effect size is often significantly smaller than initially believed (Ioannidis and Panagiotou, 2011).

Another issue inherently associated with large human studies and generally with studies handling big datasets is information availability and reproducibility. As is known from the field of microarrays, data is often incomplete or incompletely annotated and the analyses hard to reproduce (Ioannidis et al., 2009) and this is still an issue in the field of small RNA-based biomarker development (Ioannidis et al., 2009).

In addition to these limitations, there is also those specifically associated with the extraction and quantification methods used for peripheral miRNA detection. As already mentioned in section Current microRNA Detection and Analysis Technologies, a variety of extraction techniques exist, each with specific biases that can greatly influence the relative weight of a certain molecular species in the sample. In addition, because the technology is rapidly evolving, there is still no clear-cut consensus as to what is the best approach to analyze large-scale small RNA profiles. These issues will settle with time, as techniques become more robust and analysis methods stabilize, but until then, they are to be carefully considered in the experimental design.

Finally, as already mentioned, there is the issue of how faithful the peripheral profile is to the original biological situation in the CNS. Although this is not most critical for biomarker discovery per se (as mentioned above, a biomarker can be simply defined as a “handle” that allows detection of a remote biological process and does not necessarily need to correlate with it), often studies strive to uncover molecules that can serve as a biomarker and be used as therapeutic targets. Evidence from PBMCs indicates that there is indeed a considerable coherence between the central neuronal response and the peripheral response in blood and that there is a cross-talk between these two tissues. It remains to be experimentally established whether this correlation can also serve to better understand neuronal physiology in the healthy and the disease situation. In this respect, the development of novel, unbiased technologies to detect even the smallest amounts of miRNAs peripherally in combination with studies in model systems has proven critical.

All in all, despite current limitations, miRNA-based biomarkers constitute an exciting field in biomedical research. For neuroscience, where the search for remotely accessible markers to understand the brain is essential for human studies, the field has elicited considerable interest and as the costs of NGS continue to decrease, it is likely to become a routine approach to generate individual patient profiles and allow targeted therapeutic intervention.

REFERENCES

Alexandrov, P. N., Dua, P., Hill, J. M., Bhattacharjee, S., Zhao, Y., and Lukiw, W. J. (2012). microRNA (miRNA) speciation in Alzheimer’s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int. J. Biochem. Mol. Biol. 3, 365–373. Available online at: http://www.ijbmb.com/files/ijbmb1211001.pdf

Alvarez, M., Khosroheidari, M., Ranchi Ravi, R., and DiStefano, J. (2012). Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney Int. 82, 1024–1032. doi: 10.1038/ki.2012.236

Anderson, A. N., Roncaroli, E., Hodges, A., Deprez, M., and Turkheimer, F. E. (2008). Chromosomal profiles of gene expression in Huntington’s disease. Brain 131(Pt 2), 381–388. doi: 10.1093/brainawm312

Arroyo, J., Chevillet, J., Kroh, E., Ruf, I., Pritchard, C., Gibson, D., et al. (2011). Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U.S.A. 108, 5003–5008. doi: 10.1073/pnas.101905108

Asare, A., Kolchinsky, S., Gao, Z., Wang, R., Raddassi, K., Bourcier, K., et al. (2008). Differential gene expression profiles are dependent upon method of peripheral blood collection and RNA isolation. BMC Genomics 9:474. doi: 10.1186/1471-2164-9-474

Baraniskin, A., Kuhnenn, J., Schlegel, U., Maghnouj, A., Zollner, H., Schmiegel, W., et al. (2012). Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol. 14, 29–33. doi: 10.1093/neuonc/nor169

Bowden, N. A., Weidenhofer, J., Scott, R. J., Schall, U., Todd, J., Michie, P. T., et al. (2006). Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophr. Res. 82, 175–183. doi: 10.1016/j.schres.2005.11.012

Burgos, K., Javaherian, A., Bomprezzi, R., Ghaffari, L., Rhodes, S., Courtright, A., et al. (2013). Identification of extracellular miRNA in human cerebrospinal fluid by next-generation sequencing. RNA 19, 712–722. doi: 10.1261/rna.036863.112

Chi, S. W., Zang, J. B., Mele, A., and Darnell, R. B. (2009). Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 460, 479–486. doi: 10.1038/nature08170

Cissell, K. A., and Deo, S. K. (2009). Trends in microRNA detection. Anal. Bioanal. Chem. 394, 1109–1116. doi: 10.1007/s00216-009-2744-6

Cogswell, J., Ward, J., Taylor, L., Waters, M., Shi, Y., Cannon, B., et al. (2008). Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. J. Alzheimers Dis. 14, 27–41. Available online at: http://iosispress.meta press.com/content/gw2umx21m3811184

Cox, M., Cairns, M., Gandhi, K., Carroll, A., Moscovis, S., Stewart, G., et al. (2010). MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in M5 whole blood. PLoS ONE 5:e12132. doi: 10.1371/journ al.pone.0012132

Davies, M. N., Volta, M., Pidsley, R., Lunnnon, K., Dicit, A., Lovestone, S., et al. (2012). Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood. Genome Biol. 13, R43. doi: 10.1186/gb-2012-13-6-r43

De Felice, B., Guida, M., Guida, M., Coppola, D., De Mieri, G., and Cotrufo, R. (2012). A miRNA signature in leucocytes from sporadic amyotrophic lateral sclerosis. Gene 508, 35–40. doi: 10.1016/j.gene.2012.07.058

de Planell-Saguer, M., and Rodicio, M. C. (2011). Analytical aspects of microRNA in diagnostics: a review. Anal. Chim. Acta 699, 134–152. doi: 10.1016/j.aca.2011.05.025

De Santis, G., Ferracin, M., Biondani, A., Caniatti, L., Rosaria Tola, M., Castelazzi, M., et al. (2010). Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J. Neuroimmunol. 226, 165–171. doi: 10.1016/j.jneuroim.2010.06.009

Desjardins, S., Belkai, E., Crete, D., Cordonnier, L., Scherrmann, J. M., Noble, F., et al. (2008). Effects of chronic morphine and morphine withdrawal on gene expression in rat peripheral blood mononuclear cells. Neuropharmacology 55, 1347–1354. doi: 10.1016/j.neuropharm.2008.08.027

Du, X., Tang, Y., Xu, H., Lit, L., Walker, W., Ashwood, P., et al. (2006). Genomic profiles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: comparisons to ischemic stroke, migraine, and Tourette syndrome. Genomics 87, 693–703. doi: 10.1016/j.ygeno.2006.02.003

Edbauer, D., Neilson, J., Foster, K., Wang, C.-F., Seeburg, D., Batterton, M., et al. (2010). Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron 65, 373–384. doi: 10.1016/j.neuron.2010.01.005
Eldh, M., Lötvlall, J., Malmhäll, C., and Ekström, K. (2012). Importance of RNA isolation methods for analysis of exosomal RNA: evaluation of different methods. Mol. Immunol. 50, 278–286. doi: 10.1016/j.molimm.2012.02.001

Frasca, M. E., Ballestar, E., Paz, M. F., Ropero, S., Setien, F., Ballestar, M. L., et al. (2005). Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci. U.S.A. 102, 10604–10609. doi: 10.1073/pnas.0508398102

Gardiner, E., Beveridge, N., Wu, J., Carr, V., Scott, R., Tooney, P., et al. (2012). Imprinted DLKI-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol. Psychiatry 17, 827–840. doi: 10.1038/mp.2011.78

Gavin, D. P., and Sharma, R. P. (2009). Chromatin from peripheral blood mononuclear cells as biomarkers for epigenetic abnormalities in schizophrenia. Cardiovase. Psychiatry Neurol. 2009;49562. doi: 10.1155/2009/49562

Gavin, D. P., and Sharma, R. P. (2010). Histone modifications, DNA methyl- lation, and schizophrenia. Neurosci. Biobehav. Rev. 34, 882–888. doi: 10.1016/j.neubiorev.2009.10.010

Geekiyane, H., Jicha, G. A., Nelson, P. T., and Chan, C. (2012). Blood serum miRNA: non-invasive biomarkers for Alzheimer’s disease. Exp. Neurol. 235, 491–496. doi: 10.1016/j.expneurol.2011.11.026

Haghikia, A., Haghikia, A., Hellwig, K., Baraniskin, A., Holzmann, A., Décard, K., et al. (2012). Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology 79, 2166–2170. doi: 10.1212/WNL.0b013e3182759621

Hunter, M., Ismail, N., Zhang, X., Aguda, B., Lee, E., Yu, L., et al. (2008). Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 3:e3694. doi: 10.1371/journal.pone.0003694

Iga, J., Ueno, S., Yamauchi, K., Numata, S., Motoki, I., Taiyosi, S., et al. (2006). Gene expression and association analysis of LIM (PDLIM) in major depression. Neurosci. Lett. 400, 203–207. doi: 10.1016/j.neulet.2006.02.044

Ilhan-Mutlu, A., Wagner, L., Wöhrer, A., Furtner, J., Widhalm, G., Marosi, C., et al. (2012). Plasma MicroRNA-21 concentration may be a useful biomarker in glioblastoma patients. Cancer Invest. 30, 615–621. doi: 10.3109/07357970.2012.708071

Inukai, S., de Lencastre, A., Turner, M., and Slack, F. (2012). Novel microRNAs differentially expressed during aging in the mouse brain. PLoS ONE 7:e40028. doi: 10.1371/journal.pone.0040028

Ioannidis, J., Allison, D., Ball, C., Couibaly, I., Cui, X., Culhane, A., et al. (2009). Repeatability of published microarray gene expression analyses. Nat. Rev. Genet. 10, 149–155. doi: 10.1038/nrg2595

Ioannidis, J., and Panagiotou, G. (2011). Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 305, 2200–2210. doi: 10.1001/jama.2011.713

Issidorides, M. R., Stefanis, C. N., Varsou, E., and Katsorichis, T. (1975). Altered chromatin ultrastructure in neutrophils of schizophrenics. Nature 258, 612–614. doi: 10.1038/258612a0

Jacquier, A. (2009). The complex eukaryotic transcriptome: unexpected pervasive transcription and novel small RNAs. Nat. Rev. Genet. 10, 833–844. doi: 10.1038/nrg2683

Keller, A., Leidinger, P., Lange, J., Borries, A., Schroers, H., Scheffler, M., et al. (2009). Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS ONE 4:e7440. doi: 10.1371/journal.pone.0007440

Kim, J., Inoue, K., Ishii, J., Vanti, W., Veronov, S., Murchison, E., et al. (2007). A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317, 1220–1224. doi: 10.1126/science.1140481

Kogure, T., Lin, W.-L., Yan, I., Braconi, C., and Patel, T. (2011). Interacellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology 54, 1237–1248. doi: 10.1002/hep.24504

Korkut, C., Li, Y., Koles, K., Brewer, C., Ashley, J., Yoshihara, M., et al. (2013). Regulation of postsynaptic retrograde signaling by presynaptic exosome release. Neuron 77, 1039–1046. doi: 10.1016/j.neuron.2013.01.013

Kumar, P., Dezo, Z., Mackenzie, C., Oestreicher, J., Agoulnik, S., Byrne, M., et al. (2013). Circulating miRNA biomarkers for Alzheimer’s Disease. PLoS ONE 8:e69807. doi: 10.1371/journal.pone.0069807
injured patients are messengers carrying mRNAs, miRNAs, and proteins. J. Neurotrauma 30, 1233–1242. doi: 10.1089/neu.2012.2596

Pepke, S., Wold, B., and Mortazavi, A. (2009). Computation for ChIP-seq and RNA-seq studies. Nat. Methods 6(11 Suppl.), S22–S32. doi: 10.1038/nmeth1533

Provençal, N., Suderman, M. J., Guillemin, C., Massart, R., Ruggiero, A., Wang, D., et al. (2012). The signature of maternal rearing in the methylome in rhesus macaque prefrontal cortex and T cells. J. Neurosci. 32, 15626–15642. doi: 10.1523/JNEUROSCI.1470-12.2012

Rajasekhar, P., Fiumara, F., Sheridan, R., Betel, D., Puthanveetil, S., Russo, I., et al. (2009). Characterization of small RNAs in Aplysia reveals a role for miR-124 in constraining synaptic plasticity through CREB. Neuron 63, 803–817. doi: 10.1016/j.neuron.2009.05.029

Rajajczak, J., Mieczkowska, K., Kucia, M., Zhang, J., Reca, R., Dvorak, P., et al. (2012). Circulating microRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol. 14, 689–700. doi: 10.1093/neuonc/noq074

Thomson, D. W., Bracken, C. P., and Goodall, G. J. (2011). Experimental strategies for microRNA target identification. Nuclear Acids Res. 39, 6845–6853. doi: 10.1093/nar/gkr330

Trushina, E., Dutta, T., Persson, X.-M. T., Mielke, M., and Petersen, R. (2013). Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer’s disease using metabolomics. PLoS ONE 8:e63644. doi: 10.1371/journal.pone.0063644

Tuason, M. T., Nossova, N., Yager, T., Tsuang, M. M., Goo, S. C., Shyu, K. G., et al. (2005). Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. Am. J. Med. Genet. B Neuropsychiatr. Genet. 133B, 1–5. doi: 10.1002/ajmg.b.30161

Turchinovich, A., Weiz, L., Langheinzi, A., and Burwinkel, B. (2011). Characterization of extracellular circulating microRNA. Nuclear Acids Res. 39, 7223–7233. doi: 10.1093/nar/gkr254

Ursini, G., Bollati, V., Fazio, L., Porcelli, A., Iacovelli, L., Catalani, A., et al. (2011). Stress-related methylation of the catechol-O-methyltransferase Val158 allele predicts human prefrontal cognition and activity. J. Neurosci. 31, 6692–6698. doi: 10.1523/JNEUROSCI.6611-10.2011

Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, L., and Lötvall, J. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–659. doi: 10.1038/ncb1596

van Heerden, J. H., Conesa, A., Stein, D. J., Montaner, D., Russell, V., and Illing, N. (2009). Parallel changes in gene expression in peripheral blood mononuclear cells and the brain after maternal separation in the mouse. BMC Res. Notes 2:195. doi: 10.1186/1756-0500-2-195

Verderio, C., Muzio, L., Turolla, E., Bergami, A., Novellino, L., Ruffini, F., et al. (2012). Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann. Neurol. 70, 610–624. doi: 10.1002/ana.23627

Vickers, K., Palmisano, B., Shouschi, B., Shamburek, R., and Remaley, A. (2011). MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13, 423–433. doi: 10.1038/ncc2210

Villossola, P., and Baranzini, S. (2012). Data integration and systems biology approaches for biomarker discovery: challenges and opportunities for multiple sclerosis. J. Neuroinmunol. 248, 38–65. doi: 10.1016/j.jneuroim.2012.01.001

Wang, K., Zhang, S., Weber, J., Baxter, D., and Galas, D. (2010). Export of microRNAs and microRNA-protective protein by mammalian cells. Nuclear Acids Res. 38, 7268–7279. doi: 10.1093/nar/gkq601

Wang, Q., Li, P., Li, A., Jiang, W., Wang, H., Wang, J., et al. (2012). Plasma specific microRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J. Exp. Clin. Cancer Res. 31, 97. doi: 10.1186/1756-9966-31-97

Williams, Z., Ben-Dov, I., Elias, R., Mihailovic, A., Brown, M., Rosenwaks, Z., et al. (2013). Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations. Proc. Natl. Acad. Sci. U.S.A. 110, 4255–4260. doi: 10.1073/pnas.1214046110

Yang, C., Wang, C., Chen, X., Chen, S., Zhang, Y., Zhi, F., et al. (2013). Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int. J. Cancer 133, 112–117. doi: 10.1002/ijc.27657

Yao, M. J., Chen, G., Zhao, P. P., Lu, M. H., Jian, J., Liu, M. F., et al. (2012). Transcriptome analysis of microRNAs in developing cerebral cortex of rat. BMC Genomics 13:232. doi: 10.1186/1471-2164-13-232

Yuferov, V., Nielsen, D. A., Levrán, O., Randesi, M., Hamon, S., Ho, A., et al. (2011). Tissue-specific DNA methylation of the human prodynorphin gene in post-mortem brain tissues and PBMCs. Pharmacogenet. Genomics 21, 185–196. doi: 10.1097/FCG.0b013e328353ebe

Zhang, R., and Su, B. (2009). Small but influential: the role of microRNAs on gene regulatory network and TURR evolution. J. Genet. Genomics 36, 1–6. doi: 10.1016/j.jgg.2011.08.006
Zhubi, A., Veldic, M., Puri, N. V., Kadriu, B., Caruncho, H., Loza, I., et al. (2009). An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. Schizophr. Res. 111, 115–122. doi: 10.1016/j.schres.2009.03.020

Zovoilis, A., Agbemenyah, H., Agis-Balboa, R., Stilling, R., Edbauer, D., Rao, P., et al. (2011). microRNA-34c is a novel target to treat dementias. EMBO J. 30, 4299–4308. doi: 10.1038/emboj.2011.327

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 30 July 2013; paper pending published: 03 October 2013; accepted: 31 October 2013; published online: 26 November 2013.

Citation: Rao P, Benito E and Fischer A (2013) MicroRNAs as biomarkers for CNS disease. Front. Mol. Neurosci. 6:39. doi: 10.3389/fnmol.2013.00039

This article was submitted to the journal Frontiers in Molecular Neuroscience. Copyright © 2013 Rao, Benito and Fischer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.